R-spondin 3 binds syndecan 4 modulating Wnt pathway: novel cancer therapeutic
The commercial opportunity is to develop antagonists of Rspo2 and/or Rspo3 for the treatment of Sdc(Syndecan)-associated disorders and for Sdc antagonists in the treatment of Rspo2- and/or Rspo3-associated disorders.
Further Information: PDF
Deutsches Krebsforschungszentrum DKFZ
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Trotting robots reveal emergence of animal gait transitions
A four-legged robot trained with machine learning by EPFL researchers has learned to avoid falls by spontaneously switching between walking, trotting, and pronking – a milestone for roboticists as well…
Innovation promises to prevent power pole-top fires
Engineers in Australia have found a new way to make power-pole insulators resistant to fire and electrical sparking, promising to prevent dangerous pole-top fires and reduce blackouts. Pole-top fires pose…
Possible alternative to antibiotics produced by bacteria
Antibacterial substance from staphylococci discovered with new mechanism of action against natural competitors. Many bacteria produce substances to gain an advantage over competitors in their highly competitive natural environment. Researchers…
